QuidelOrtho (NASDAQ:QDEL) Releases FY 2025 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 2.070-2.570 for the period, compared to the consensus earnings per share estimate of 2.380. The company issued revenue guidance of $2.6 billion-$2.8 billion, compared to the consensus revenue estimate of $2.7 billion.

Analysts Set New Price Targets

QDEL has been the topic of a number of research analyst reports. UBS Group dropped their target price on shares of QuidelOrtho from $45.00 to $29.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Jefferies Financial Group upgraded shares of QuidelOrtho from a "hold" rating to a "buy" rating and set a $44.00 target price on the stock in a research note on Thursday, May 8th. JPMorgan Chase & Co. dropped their price objective on shares of QuidelOrtho from $38.00 to $25.00 and set an "underweight" rating on the stock in a research note on Monday, April 21st. Finally, Wall Street Zen raised shares of QuidelOrtho from a "hold" rating to a "buy" rating in a report on Friday, June 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $44.33.

QuidelOrtho Stock Up 0.6%

Shares of NASDAQ QDEL traded up $0.17 during mid-day trading on Friday, reaching $28.87. 10,803,737 shares of the company were exchanged, compared to its average volume of 1,136,014. The company has a quick ratio of 0.66, a current ratio of 1.20 and a debt-to-equity ratio of 0.70. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -5.81 and a beta of 0.10. QuidelOrtho has a 1 year low of $23.77 and a 1 year high of $49.45. The firm has a 50-day moving average of $29.84 and a 200 day moving average of $35.93.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.74 earnings per share for the quarter, topping analysts' consensus estimates of $0.61 by $0.13. The firm had revenue of $692.80 million during the quarter, compared to analysts' expectations of $694.97 million. QuidelOrtho had a positive return on equity of 4.71% and a negative net margin of 12.07%. The firm's quarterly revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.44 EPS. On average, research analysts expect that QuidelOrtho will post 2.3 earnings per share for the current year.

Institutional Investors Weigh In On QuidelOrtho

Hedge funds have recently made changes to their positions in the stock. Focus Partners Wealth increased its position in QuidelOrtho by 210.9% during the 1st quarter. Focus Partners Wealth now owns 20,454 shares of the company's stock valued at $715,000 after buying an additional 13,876 shares in the last quarter. Royal Bank of Canada grew its holdings in QuidelOrtho by 1,218.7% during the first quarter. Royal Bank of Canada now owns 80,193 shares of the company's stock worth $2,803,000 after acquiring an additional 74,112 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in QuidelOrtho by 10.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company's stock worth $7,987,000 after acquiring an additional 21,968 shares during the period. 99.00% of the stock is currently owned by hedge funds and other institutional investors.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.